BioXcel Therapeutics, Inc.
General ticker "BTAI" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $55.4M (TTM average)
BioXcel Therapeutics, Inc. follows the US Stock Market performance with the rate: 8.1%.
Estimated limits based on current volatility of 5.8%: low 1.89$, high 2.12$
Factors to consider:
- Total employees count: 80 as of 2023
- Top business risk factors: Operational and conduct risks, Transition to commercial activities with unforeseen expenses, Potential disputes with bioxcel LLC, Third-party risks, Labor/talent shortage/retention
- Current price 32.8% below estimated low
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [3.11$, 13.05$]
- 2025-12-31 to 2026-12-31 estimated range: [1.83$, 7.80$]
Financial Metrics affecting the BTAI estimates:
- Positive: with PPE of -0.2 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -497.02 <= 0.33
- Negative: Shareholder equity ratio, % of -242.84 <= 18.93
- Negative: negative Industry operating cash flow (median)
- Negative: negative Net income
- Negative: Industry earnings per price (median), % of -16.34 <= 0
- Negative: negative Industry operating income (median)
- Negative: Interest expense per share per price, % of 104.40 > 3.41
Short-term BTAI quotes
Long-term BTAI plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.38MM | $1.38MM | $2.27MM |
| Operating Expenses | $160.02MM | $173.16MM | $69.51MM |
| Operating Income | $-159.65MM | $-171.78MM | $-67.25MM |
| Non-Operating Income | $-6.11MM | $-7.27MM | $7.65MM |
| Interest Expense | $8.21MM | $13.31MM | $15.13MM |
| R&D Expense | $91.24MM | $84.33MM | $30.43MM |
| Income(Loss) | $-165.76MM | $-179.05MM | $-59.60MM |
| Profit(Loss)* | $-165.76MM | $-179.05MM | $-59.60MM |
| Stockholders Equity | $76.78MM | $-56.51MM | $-93.10MM |
| Inventory | $1.99MM | $1.99MM | $0.68MM |
| Assets | $205.85MM | $73.70MM | $38.34MM |
| Operating Cash Flow | $-135.34MM | $-155.01MM | $-72.03MM |
| Capital expenditure | $0.14MM | $0.02MM | $0.00MM |
| Investing Cash Flow | $-0.14MM | $-0.02MM | $0.00MM |
| Financing Cash Flow | $96.24MM | $26.52MM | $36.66MM |
| Earnings Per Share** | $-94.67 | $-98.35 | $-23.51 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.